摘要
目的探讨奥沙利铂(L-OHP)联合化疗对晚期结肠癌的疗效和安全性及对血清肿瘤坏死因子α(TNF-α)、白细胞介素(IL)2水平的影响。方法将2008年3月至2013年8月崇阳县中医院收治的83例晚期结肠癌患者采用随机数字表法分为两组:对照组(43例)采用亚叶酸钙+5氟尿嘧啶进行化疗,观察组(40例)在对照组的基础上加用L-OHP治疗。治疗结束后,观察两组患者的疗效、不良反应及血清TNF-α、IL-2水平的变化情况。结果观察组化疗方案的总有效率显著优于对照组(P=0.013);两组不良反应发生率比较差异均无统计学意义(P>0.05);治疗后,两组患者的血清TNF-α水平均显著下降(P<0.01),且观察组下降幅度大于对照组(P<0.01),两组患者的IL-2水平均显著升高(P<0.01),且观察组上升降幅度大于对照组(P<0.01)。结论在晚期结肠癌的治疗中,采用L-OHP联合亚叶酸钙、氟尿嘧啶化疗,可以提高疗效,改善患者生存质量,值得临床运用。
Objective To investigate the therapeutic efficacy and safety of L-OHP + 5-FL/CF combined therapy for colon carcinoma,and the influence on the level of TNF-α,IL-2 in serum.Methods A total of 83 patients with advanced stage colon carcinoma admitted to Chongyang County Hospital of Traditional Chinese Medicine from Mar.2008 to Aug.2013 were randomly divided into treatment group of 40 cases and control group of 43 cases by random-number table.The control group was treated by 5-FL/CF,and the observation group was treated by the combined therpay of L-OHP + 5-FL/CF.The total effective rate,incidence of adverse reactions and TNF-α,IL-2 in serum of the two groups were compared.Results The total effective rate of the observation group was significantly better than the control group(P =0.013).The incidence of adverse reactions of the two groups were not statisticcally significantly different(P 〉 0.05) ; after treatment,serum TNF-α level in patients of the two groups were both significantly decreased(P 〈 0.01),and the observation group was much lower than the control group(P 〈 0.01),IL-2 of both groups were significantly increased(P 〈 0.01),and the observation group increase amplitude was significantly larger than the control group(P 〈 0.01).Conclusion The therapeutic efficacy of combined L-OHP + 5-FL/CF for colon carcinoma of advance stage is improved,which can improve the quality of life of the patients,and thus is worthy of application in clinical.
出处
《医学综述》
2014年第10期1883-1885,共3页
Medical Recapitulate
关键词
晚期结肠癌
亚叶酸钙
氟脲嘧啶
奥沙利铂
白细胞介素2
Advanced stage colon carcinoma
Calcium folinate
Fluorouracil
Oxaliplatin
Interleukin-2